Gastroenterology April 2026 Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease

This study evaluates how effectively a specific blood biomarker, phosphatidylethanol (PEth), can forecast severe liver complications in individuals at risk for alcohol-related liver disease. While traditional noninvasive tests primarily measure existing liver scarring or fibrosis, this research demonstrates that tracking PEth levels provides a distinct, independent layer of prognostic data regarding a patient's future health. Although the predictive accuracy of a single PEth measurement fades over time, the study highlights that monitoring changes in alcohol intakethrough repeated testing is a powerful tool for identifying those most likely to experience hepatic failure. Ultimately, the findings suggest that integrating this chemical marker with standard physical assessments offers a more comprehensive view of disease progression than using either method in isolation.